CoChat

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

Open access

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Exogenous administration of glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonists such as an exendin-4 has direct beneficial effects on the cardiovascular system. However, their effects on atherosclerogenesis have not been elucidated. The aim of this study was to investigate the effects of GLP-1 on accumulation of monocytes/macrophages on the vascular wall, one of the earliest steps in atherosclerogenesis. RESEARCH DESIGN AND METHODS: After continuous infusion of low (300 pmol · kg−1 · day−1) or high (24 nmol · kg−1 · day−1) dose of exendin-4 in C57BL/6 or apolipoprotein E–deficient mice (apoE−/−), we evaluated monocyte adhesion to the endothelia of thoracic aorta and arteriosclerotic lesions around the aortic valve. The effects of exendin-4 were investigated in mouse macrophages and human monocytes. RESULTS: Treatment with exendin-4 significantly inhibited monocytic adhesion in the aortas of C57BL/6 mice without affecting metabolic parameters. In apoE−/− mice, the same treatment reduced monocyte adhesion to the endothelium and suppressed atherosclerogenesis. In vitro treatment of mouse macrophages with exendin-4 suppressed lipopolysaccharide-induced mRNA expression of tumor necrosis factor-α and monocyte chemoattractant protein-1, and suppressed nuclear translocation of p65, a component of nuclear factor-κB. This effect was reversed by either MDL-12330A, a cAMP inhibitor or PKI14-22, a protein kinase A–specific inhibitor. In human monocytes, exendin-4 reduced the expression of CD11b. CONCLUSIONS: Our data suggested that GLP-1 receptor agonists reduced monocyte/macrophage accumulation in the arterial wall by inhibiting the inflammatory response in macrophages, and that this effect may contribute to the attenuation of atherosclerotic lesion by exendin-4.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db09-1694

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Expression of GLP-1 receptor on macrophages. A: Expression of GLP-1 receptor in murine lung and liver, isolated murine islets, isolated murine macrophages (Mϕs), cultured murine endothelial cells (ECs), cultured murine smooth muscle cells (SMCs), human monocyte derived line, THP-1 cells, and HUVECs. B: Expression of GLP-1 receptor in human monocytes from healthy subjects. C: Immunohistochemical staining of GLP-1 receptor (green) and Mac-2, a marker of macrophages (red) in atherosclerotic lesions of apoE−/− mice. (A high-quality digital representation of this figure is available in the online issue.)
FIG. 1. Expression of GLP-1 receptor on macrophages. A: Expression of GLP-1 receptor in murine lung and liver, isolated murine islets, isolated murine macrophages (Mϕs), cultured murine endothelial cells (ECs), cultured murine smooth muscle cells (SMCs), human monocyte derived line, THP-1 cells, and HUVECs. B: Expression of GLP-1 receptor in human monocytes from healthy subjects. C: Immunohistochemical staining of GLP-1 receptor (green) and Mac-2, a marker of macrophages (red) in atherosclerotic lesions of apoE−/− mice. (A high-quality digital representation of this figure is available in the online issue.)CC BY-NC-ND · PubMed Central
FIG. 2. Exendin-4 reduced monocytic adhesion to the endothelium in C57BL/6 mice. A: Changes in body weight during treatment with exendin-4 in C57BL/6 mice (n = 6 each). B: Blood glucose concentrations during IPGTT after 24-day treatment with exendin-4 (n = 6 each). C: Plasma insulin levels during IPGTT after 24-day treatment with exendin-4 (n = 6 each). D: Results of insulin tolerance test in each group after 24-day treatment with exendin-4 (n = 6 each). E: The density of adherent Mac-2–positive cells on endothelial cells at branching areas in each group of mice after 28-day treatment (n = 6) with representative en face views of immunohistologic staining with Mac-2 antibody. Data are mean ± SEM. *P < 0.05 versus high-dose group, +P < 0.05 versus low-dose group. (A high-quality digital representation of this figure is available in the online issue.)
FIG. 2. Exendin-4 reduced monocytic adhesion to the endothelium in C57BL/6 mice. A: Changes in body weight during treatment with exendin-4 in C57BL/6 mice (n = 6 each). B: Blood glucose concentrations during IPGTT after 24-day treatment with exendin-4 (n = 6 each). C: Plasma insulin levels during IPGTT after 24-day treatment with exendin-4 (n = 6 each). D: Results of insulin tolerance test in each group after 24-day treatment with exendin-4 (n = 6 each). E: The density of adherent Mac-2–positive cells on endothelial cells at branching areas in each group of mice after 28-day treatment (n = 6) with representative en face views of immunohistologic staining with Mac-2 antibody. Data are mean ± SEM. *P < 0.05 versus high-dose group, +P < 0.05 versus low-dose group. (A high-quality digital representation of this figure is available in the online issue.)CC BY-NC-ND · PubMed Central
FIG. 3. The metabolic effect of exendin-4 in apoE−/− mice. A: Changes in body weight during exendin-4 treatment in apoE−/− mice (n = 13). B: Blood glucose concentrations during IPGTT after 24-day treatment with exendin-4 (n = 6). C: Plasma insulin levels during IPGTT after 24-day treatment with exendin-4 (n = 6). D: Results of insulin tolerance test in each group after 24-day treatment with exendin-4 (n = 6). Data are mean ± SEM. *P < 0.01 versus high-dose group, +P < 0.01 versus low-dose group.
FIG. 3. The metabolic effect of exendin-4 in apoE−/− mice. A: Changes in body weight during exendin-4 treatment in apoE−/− mice (n = 13). B: Blood glucose concentrations during IPGTT after 24-day treatment with exendin-4 (n = 6). C: Plasma insulin levels during IPGTT after 24-day treatment with exendin-4 (n = 6). D: Results of insulin tolerance test in each group after 24-day treatment with exendin-4 (n = 6). Data are mean ± SEM. *P < 0.01 versus high-dose group, +P < 0.01 versus low-dose group.CC BY-NC-ND · PubMed Central
FIG. 4. Exendin-4 reduced monocyte adhesion to the endothelium and atherosclerotic lesions in apoE−/− mice. A: En face immunohistochemical staining with Mac-2 antibody of the aorta of each group. The density of adherent Mac-2–positive cells on the endothelium at branching areas in each group of mice after 28-day treatment (n = 7) and representative en face views of immunohistologic staining with Mac-2 antibody. B: Aortas harvested from each group of mice after 28-day treatment were used for isolation of total RNA. The mRNA expression levels of ICAM-1 and VCAM-1 were determined by quantitative RT-PCR. Relative gene expression is displayed as the level of expression in the test mice relative to that in the control group (set at 1.0, n = 5–7). C: Representative histologic sections of the aortic sinuses stained with oil red O after 28-day treatment. The mean area of oil red O–positive lesions was determined (n = 20). Data are mean ± SEM. *P < 0.05 versus control group. (A high-quality digital representation of this figure is available in the online issue.)
FIG. 4. Exendin-4 reduced monocyte adhesion to the endothelium and atherosclerotic lesions in apoE−/− mice. A: En face immunohistochemical staining with Mac-2 antibody of the aorta of each group. The density of adherent Mac-2–positive cells on the endothelium at branching areas in each group of mice after 28-day treatment (n = 7) and representative en face views of immunohistologic staining with Mac-2 antibody. B: Aortas harvested from each group of mice after 28-day treatment were used for isolation of total RNA. The mRNA expression levels of ICAM-1 and VCAM-1 were determined by quantitative RT-PCR. Relative gene expression is displayed as the level of expression in the test mice relative to that in the control group (set at 1.0, n = 5–7). C: Representative histologic sections of the aortic sinuses stained with oil red O after 28-day treatment. The mean area of oil red O–positive lesions was determined (n = 20). Data are mean ± SEM. *P < 0.05 versus control group. (A high-quality digital representation of this figure is available in the online issue.)CC BY-NC-ND · PubMed Central
FIG. 5. Exendin-4 reduced the inflammatory response through cAMP signaling pathway in macrophages, and reduced the expression of CD11b in human monocytes. A: Peritoneal macrophages isolated from 8-week-old C57BL/6 mice were incubated with various concentrations of exendin-4 (0.03–3 nmol/l) for 1 h followed by treatment with LPS (1 μg/ml) for 1 h. Then, macrophages were used for isolation of total RNA. The mRNA expression levels of TNF-α and MCP-1 were determined by quantitative RT-PCR. Relative gene expression is displayed as the level of expression in peritoneal macrophages without the addition of exendin-4 set at 1.0 (n = 4–5). B: Peritoneal macrophages were preincubated with 5 μmol/l MDL-12330A for 30 min before the addition of 0.3 nmol/l exendin-4 and then incubated with LPS (1 μg/ml) for 1 h. Then, macrophages were used for isolation of total RNA (n = 4–6). C: Peritoneal macrophages were incubated with 0.3 nmol/l exendin-4 or 10 μmol/l forskolin for 1 h followed by LPS (1 μg/ml) for 1 h. Then, macrophages were used for isolation of total RNA (n = 4–5). D: Peritoneal macrophages were preincubated with 10 μmol/l PKI14-22 for 30 min before the addition of 0.3 nmol/l exendin-4 and then incubated with LPS (1 μg/ml) for 1 h. Then, macrophages were used for isolation of total RNA (n = 4–5). E: Peritoneal macrophages were preincubated with 5 μmol/l MDL-12330A for 30 min before the addition of 0.3 nmol/l exendin-4 and then incubated with LPS (1 μg/ml) for 1 h. Then, macrophages were used for isolation of nuclear protein extracts. The nuclear level of NF-κB p65 was determined by enzyme-linked immunosorbent assay (ELISA) (n = 3–4). F: Human monocytes isolated from healthy volunteers were incubated without or with various concentrations of exendin-4 (0.03–3 nmol/l) for 24 h. Then, the surface expression of CD11b was assessed by flow cytometry. Data are median fluorescence intensity relative to the control. *P < 0.05 versus the control group.
FIG. 5. Exendin-4 reduced the inflammatory response through cAMP signaling pathway in macrophages, and reduced the expression of CD11b in human monocytes. A: Peritoneal macrophages isolated from 8-week-old C57BL/6 mice were incubated with various concentrations of exendin-4 (0.03–3 nmol/l) for 1 h followed by treatment with LPS (1 μg/ml) for 1 h. Then, macrophages were used for isolation of total RNA. The mRNA expression levels of TNF-α and MCP-1 were determined by quantitative RT-PCR. Relative gene expression is displayed as the level of expression in peritoneal macrophages without the addition of exendin-4 set at 1.0 (n = 4–5). B: Peritoneal macrophages were preincubated with 5 μmol/l MDL-12330A for 30 min before the addition of 0.3 nmol/l exendin-4 and then incubated with LPS (1 μg/ml) for 1 h. Then, macrophages were used for isolation of total RNA (n = 4–6). C: Peritoneal macrophages were incubated with 0.3 nmol/l exendin-4 or 10 μmol/l forskolin for 1 h followed by LPS (1 μg/ml) for 1 h. Then, macrophages were used for isolation of total RNA (n = 4–5). D: Peritoneal macrophages were preincubated with 10 μmol/l PKI14-22 for 30 min before the addition of 0.3 nmol/l exendin-4 and then incubated with LPS (1 μg/ml) for 1 h. Then, macrophages were used for isolation of total RNA (n = 4–5). E: Peritoneal macrophages were preincubated with 5 μmol/l MDL-12330A for 30 min before the addition of 0.3 nmol/l exendin-4 and then incubated with LPS (1 μg/ml) for 1 h. Then, macrophages were used for isolation of nuclear protein extracts. The nuclear level of NF-κB p65 was determined by enzyme-linked immunosorbent assay (ELISA) (n = 3–4). F: Human monocytes isolated from healthy volunteers were incubated without or with various concentrations of exendin-4 (0.03–3 nmol/l) for 24 h. Then, the surface expression of CD11b was assessed by flow cytometry. Data are median fluorescence intensity relative to the control. *P < 0.05 versus the control group.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

Metadata

Authors
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H.
Affiliations
Juntendo University (JP)
Corresponding author
  • Mita, Tomoya
  • Watada, Hirotaka
Venue
Diabetes
Published
2010-01-12
Volume
59
Issue
4
Pages
1030-1037
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2142097676
Cited by
548
References
38
Citations by year
2026: 31 · 2025: 25 · 2024: 34 · 2023: 27 · 2022: 37 · 2021: 33 · 2020: 27 · 2019: 25 · 2018: 36 · 2017: 32 · 2016: 41 · 2015: 46 · 2014: 36 · 2013: 35 · 2012: 43
FWCI
16.23
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
exendin-4, GLP-1 receptor agonists, monocyte adhesion, endothelial cells, atherosclerosis, macrophage accumulation, ApoE-deficient mice, NF-κB, TNF-α, MCP-1, cAMP signaling, protein kinase A, CD11b, inflammation
MeSH terms
Exenatide, Animals, Aorta, Cell Adhesion, Endothelium, Vascular, Flow Cytometry, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Islets of Langerhans, Liver, Lung, Male, Mice, Inbred C57BL, Monocytes, Peptides, Venoms, Reverse Transcriptase Polymerase Chain Reaction, Atherosclerosis, Mice, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.